One out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 35 points (-0.2%) at 18,458 as of Tuesday, July 26, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,840 issues advancing vs. 1,054 declining with 156 unchanged.

The Health Care sector currently sits up 0.3% versus the S&P 500, which is unchanged. A company within the sector that fell today was

AstraZeneca

(

AZN

), up 1.0%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3.

Bristol-Myers Squibb Company

(

BMY

) is one of the companies pushing the Health Care sector lower today. As of noon trading, Bristol-Myers Squibb Company is down $0.45 (-0.6%) to $75.11 on light volume. Thus far, 1.6 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 5.9 million shares. The stock has ranged in price between $75.06-$75.87 after having opened the day at $75.77 as compared to the previous trading day's close of $75.56.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $126.3 billion and is part of the drugs industry. Shares are up 9.8% year-to-date as of the close of trading on Monday. Currently there are 8 analysts that rate Bristol-Myers Squibb Company a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Bristol-Myers Squibb Company

as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Bristol-Myers Squibb Company Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Celgene

(

CELG

) is down $1.47 (-1.4%) to $106.46 on heavy volume. Thus far, 3.5 million shares of Celgene exchanged hands as compared to its average daily volume of 4.4 million shares. The stock has ranged in price between $105.49-$108.03 after having opened the day at $105.99 as compared to the previous trading day's close of $107.93.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. Celgene has a market cap of $83.3 billion and is part of the drugs industry. Shares are down 9.9% year-to-date as of the close of trading on Monday. Currently there are 14 analysts that rate Celgene a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Celgene

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, expanding profit margins, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Celgene Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Gilead

(

GILD

) is down $7.71 (-8.7%) to $80.84 on heavy volume. Thus far, 30.5 million shares of Gilead exchanged hands as compared to its average daily volume of 9.4 million shares. The stock has ranged in price between $80.81-$84.15 after having opened the day at $84.05 as compared to the previous trading day's close of $88.55.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $115.3 billion and is part of the drugs industry. Shares are down 12.5% year-to-date as of the close of trading on Monday. Currently there are 10 analysts that rate Gilead a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Gilead

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, attractive valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Gilead Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).